Recent Postings to


Worst Pills, Best Pills Newsletter Articles

  View the entire December 2018 issue in PDF format

  View the entire November 2018 issue in PDF format

  View the entire October 2018 issue in PDF format

  • False-Hope Alzheimer’s Disease Drugs
    (October 2018)
    The FDA has approved four drugs for treating Alzheimer’s disease, a devastating brain disorder that affects nearly 6 million Americans, most of whom are elderly. Learn why we have designated each of these drugs as Do Not Use.
  • New Research Shows Drugs Associated with a Risk of Depression Are Widely Used
    (October 2018)
    In this article, we summarize the results of a recent research study showing that use of medications that have depression as a potential adverse effect is very common. We also identify some of the many prescription medications that can cause depression symptoms, including suicidal thoughts or behavior.
  • Review of Lamotrigine (LAMICTAL)
    (October 2018)
    For certain types of epilepsy, lamotrigine is an appropriate treatment for preventing seizures. Learn about the common and serious adverse effects that can occur while taking this drug and how to take this drug safely.
  • FDA Announces Recalls of Certain Valsartan-Containing Medications Because of Cancer-Causing Contaminant
    (October 2018)
    We have received numerous questions from readers asking what to do about the recent recalls of valsartan-containing drugs sold by certain companies that were found to be tainted with a probable carcinogen. In this article, we offer advice for those patients who have been taking valsartan.
  • Question & Answer
    (October 2018)
    Several readers have asked us whether the FDA’s recent approval of a drug that reverses the anticoagulant effect of apixaban (ELIQUIS) and rivaroxaban (XARELTO) alters our classification of these two drugs as Do Not Use. Read our answer.
  • HHS Inspector General Documents Big Pharma’s Price Gouging of Seniors
    (October 2018)
    In his editor’s column, Dr. Michael Carome discusses the implications of a recent government report which found that annual out-of-pocket expenses for brand-name drugs covered under Medicare Part D have skyrocketed in recent years.

Additional Information from Public Citizen

Copyright © 2018 Public Citizen's Health Research Group. All rights reserved.